X0202 SCHEDULE 13G/A 0001193125-21-170441 0001234950 XXXXXXXX LIVE 6 Common Stock, par value $0.005 per share 02/10/2026 0000748592 Ernexa Therapeutics Inc. 114082407 1035 Cambridge Street Suite 18A Cambridge MA 02141 Rule 13d-1(c) John D. Halpern b X1 0 66751 0 66751 66751 N 5.6 IN John D. Halpern and Katherine H. Halpern are trustees of the John D. Halpern Revocable Trust (the "Trust"). By virtue of this relationship, Mr. Halpern may be deemed to share beneficial ownership of the securities held of record by the Trust. The number of shares of Common Stock owned by the Reporting Person reflects Ernexa Therapeutics Inc.'s (the "Issuer") 1-for-15 reverse stock split of its outstanding shares of common stock, par value $0.005 per share (the "Common Stock") that was effected on June 10, 2025 and the Issuer's 1-for-25 reverse stock split of its outstanding shares of Common Stock that was effected on May 4, 2026 (collectively, the "Reverse Stock Splits"), each as reported. Rows 6, 8, and 9 consist of (i) 46,445 shares of Common Stock of the Issuer held by the Trust, (ii) 306 shares of Common Stock issuable upon the exercise of pre-funded warrants to purchase 306 shares of Common Stock at an exercise price of $1.8750 per share (the "Pre-funded Warrants") and (iii) 20,000 shares of Common Stock issuable upon the exercise of warrants to purchase 20,000 shares of Common Stock at an exercise price of $17.00 per share (the "Common Warrants" and together with the Pre-funded Warrants, the "Warrants"). Row 11 is calculated based on an aggregate of 1,186,639 shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 1,166,333 shares of Common Stock of the Issuer outstanding as of May 8, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2026, and (ii) 20,306 shares of Common Stock of the Issuer issuable to the Reporting Person upon exercise of the Warrants within 60 days, and which, for (ii), is deemed outstanding pursuant to Rule 13d-3(d)(1)(i). This Amendment No. 6 to Schedule 13G amends the Schedule 13G filed by the Reporting Persons named therein on May 15, 2025, as amended and supplemented to date. Katherine H. Halpern b X1 0 66751 0 66751 66751 N 5.6 IN As noted above, John D. Halpern and Katherine H. Halpern are trustees of the Trust. By virtue of this relationship, Ms. Halpern may be deemed to share beneficial ownership of the securities held of record by the Trust. The number of shares of Common Stock owned by the Reporting Person reflects the Reverse Stock Splits, as reported. Rows 6, 8, and 9 are based on (i) 46,445 shares of Common Stock of the Issuer held by the Trust, (ii) 306 shares of Common Stock issuable upon the exercise of Pre-funded Warrants, and (iii) 20,000 shares of Common Stock issuable upon the exercise of the Common Warrants. Row 11 is calculated based on an aggregate of 1,186,639 shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 1,166,333 shares of Common Stock of the Issuer outstanding as of May 8, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 11, 2026, and (ii) 20,306 shares of Common Stock of the Issuer issuable to the Reporting Person upon exercise of the Warrants within 60 days, and which, for (ii), is deemed outstanding pursuant to Rule 13d-3(d)(1)(i). Ernexa Therapeutics Inc. 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141 John D. Halpern Katherine H. Halpern P.O. Box 540 Portsmouth, New Hampshire 03802 United States Y See Row 9 of cover page for each Reporting Person. See Row 11 of cover page for each Reporting Person. See Row 5 of cover page for each Reporting Person. See Row 6 of cover page for each Reporting Person. See Row 7 of cover page for each Reporting Person. See Row 8 of cover page for each Reporting Person. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. John D. Halpern /s/ John D. Halpern 05/15/2026 Katherine H. Halpern /s/ Katherine H. Halpern 05/15/2026